Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again

Kenneth R. Cooke

doi:10.1111/j.1399-3046.2005.00450.x

Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again

Kenneth R. Cooke

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Allogeneic hematopoietic stern cell transplantation (SCT) is the only curative therapeutic option for a number of malignant and non-malignant conditions, but the success of this treatment strategy is limited by several side effects. Diffuse lung injury is a major complication of SCT that responds poorly to standard treatment and significantly contributes to transplant related morbidity and mortality. Lung injury occurs in both acute and chronic forms and can be either infectious or non-infectious in nature. Acute, non-infectious lung injury following SCT has been defined as idiopathic pneumonia syndrome (IPS). This review will outline the clinical spectrum, risk factors, and pathogeneses of IPS and discuss how current approaches to therapy are being influenced by insights generated using animal models of disease.

Original language	English (US)
Pages (from-to)	25-36
Number of pages	12
Journal	Pediatric transplantation
Volume	9
Issue number	SUPPL. 7
DOIs	https://doi.org/10.1111/j.1399-3046.2005.00450.x
State	Published - Dec 2005
Externally published	Yes

Keywords

Cytokines
Idiopathic
Inflammation
Pneumonia
Syndrome
Tumor necrosis factor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Transplantation

Access to Document

10.1111/j.1399-3046.2005.00450.x

Cite this

@article{cfc0c18085ff4a0cb3de8f71e8a32af0,

title = "Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again",

abstract = "Allogeneic hematopoietic stern cell transplantation (SCT) is the only curative therapeutic option for a number of malignant and non-malignant conditions, but the success of this treatment strategy is limited by several side effects. Diffuse lung injury is a major complication of SCT that responds poorly to standard treatment and significantly contributes to transplant related morbidity and mortality. Lung injury occurs in both acute and chronic forms and can be either infectious or non-infectious in nature. Acute, non-infectious lung injury following SCT has been defined as idiopathic pneumonia syndrome (IPS). This review will outline the clinical spectrum, risk factors, and pathogeneses of IPS and discuss how current approaches to therapy are being influenced by insights generated using animal models of disease.",

keywords = "Cytokines, Idiopathic, Inflammation, Pneumonia, Syndrome, Tumor necrosis factor",

author = "Cooke, {Kenneth R.}",

year = "2005",

month = dec,

doi = "10.1111/j.1399-3046.2005.00450.x",

language = "English (US)",

volume = "9",

pages = "25--36",

journal = "Pediatric transplantation",

issn = "1397-3142",

publisher = "Wiley-Blackwell",

number = "SUPPL. 7",

}

TY - JOUR

T1 - Acute lung injury after allogeneic stem cell transplantation

T2 - From the clinic, to the bench and back again

AU - Cooke, Kenneth R.

PY - 2005/12

Y1 - 2005/12

N2 - Allogeneic hematopoietic stern cell transplantation (SCT) is the only curative therapeutic option for a number of malignant and non-malignant conditions, but the success of this treatment strategy is limited by several side effects. Diffuse lung injury is a major complication of SCT that responds poorly to standard treatment and significantly contributes to transplant related morbidity and mortality. Lung injury occurs in both acute and chronic forms and can be either infectious or non-infectious in nature. Acute, non-infectious lung injury following SCT has been defined as idiopathic pneumonia syndrome (IPS). This review will outline the clinical spectrum, risk factors, and pathogeneses of IPS and discuss how current approaches to therapy are being influenced by insights generated using animal models of disease.

AB - Allogeneic hematopoietic stern cell transplantation (SCT) is the only curative therapeutic option for a number of malignant and non-malignant conditions, but the success of this treatment strategy is limited by several side effects. Diffuse lung injury is a major complication of SCT that responds poorly to standard treatment and significantly contributes to transplant related morbidity and mortality. Lung injury occurs in both acute and chronic forms and can be either infectious or non-infectious in nature. Acute, non-infectious lung injury following SCT has been defined as idiopathic pneumonia syndrome (IPS). This review will outline the clinical spectrum, risk factors, and pathogeneses of IPS and discuss how current approaches to therapy are being influenced by insights generated using animal models of disease.

KW - Cytokines

KW - Idiopathic

KW - Inflammation

KW - Pneumonia

KW - Syndrome

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=28344449643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28344449643&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2005.00450.x

DO - 10.1111/j.1399-3046.2005.00450.x

M3 - Article

C2 - 16305615

AN - SCOPUS:28344449643

SN - 1397-3142

VL - 9

SP - 25

EP - 36

JO - Pediatric transplantation

JF - Pediatric transplantation

IS - SUPPL. 7

ER -

Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this